Baton Rouge, LOUISIANA3 Active Studies

Atopic Dermatitis Clinical Trials in Baton Rouge, LOUISIANA

Find 3 actively recruiting atopic dermatitis clinical trials in Baton Rouge, LOUISIANA. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
626
Enrolling

Recruiting Atopic Dermatitis Studies in Baton Rouge

About Atopic Dermatitis Clinical Trials in Baton Rouge

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 3 atopic dermatitis clinical trials recruiting participants in Baton Rouge, LOUISIANA. These studies are seeking a combined 626 participants. Research is being sponsored by AVEO Pharmaceuticals, Inc., Zura Bio Inc, Hangzhou Yirui Pharmaceutical Technology Co., Ltd. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in Baton Rouge — FAQ

Are there atopic dermatitis clinical trials in Baton Rouge?

Yes, there are 3 atopic dermatitis clinical trials currently recruiting in Baton Rouge, LOUISIANA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Baton Rouge?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Baton Rouge research site will contact you about next steps.

Are clinical trials in Baton Rouge free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Baton Rouge studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 3 active trials in Baton Rouge are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated March 2, 2026 from ClinicalTrials.gov